Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2012 1
2014 1
2015 2
2016 1
2019 1
2020 1
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.
Lak NSM, van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, van Paemel R, Vandeputte C, De Preter K, De Wilde B, Chicard M, Iddir Y, Schleiermacher G, Ruhen O, Shipley J, Fiocco M, Merks JHM, van Noesel MM, van der Schoot CE, Tytgat GAM, Stutterheim J. Lak NSM, et al. Among authors: zappeij kannegieter l. JCO Precis Oncol. 2023 Jan;7:e2200113. doi: 10.1200/PO.22.00113. JCO Precis Oncol. 2023. PMID: 36652664 Free PMC article.
Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR.
van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, Lugtigheid M, Gelineau NU, Lak NSM, Zwijnenburg DA, Koster J, Stutterheim J, van der Schoot CE, Tytgat GAM. van Zogchel LMJ, et al. Among authors: zappeij kannegieter l. Cancers (Basel). 2021 Jan 5;13(1):150. doi: 10.3390/cancers13010150. Cancers (Basel). 2021. PMID: 33466359 Free PMC article.
Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM, Voormanns TL, Zappeij-Kannegieter L, van Zogchel LMJ, Fiocco M, van Noesel MM, Merks JHM, van der Schoot CE, Tytgat GAM, Stutterheim J. Lak NSM, et al. Among authors: zappeij kannegieter l. Clin Cancer Res. 2021 Oct 15;27(20):5576-5585. doi: 10.1158/1078-0432.CCR-21-1083. Epub 2021 Jul 20. Clin Cancer Res. 2021. PMID: 34285060 Free PMC article.
Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma.
van Zogchel LMJ, van Wezel EM, van Wijk J, Stutterheim J, Bruins WSC, Zappeij-Kannegieter L, Slager TJE, Schumacher-Kuckelkorn R, Verly IRN, van der Schoot CE, Tytgat GAM. van Zogchel LMJ, et al. Among authors: zappeij kannegieter l. JCO Precis Oncol. 2020 Apr 14;4:PO.19.00261. doi: 10.1200/PO.19.00261. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923888 Free PMC article.
Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA. van Wezel EM, et al. Among authors: zappeij kannegieter l. J Mol Diagn. 2015 Jan;17(1):43-52. doi: 10.1016/j.jmoldx.2014.09.005. Epub 2014 Oct 24. J Mol Diagn. 2015. PMID: 25445214 Free article.
Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. Stutterheim J, et al. Among authors: zappeij kannegieter l. J Mol Diagn. 2012 Mar-Apr;14(2):168-75. doi: 10.1016/j.jmoldx.2011.12.002. Epub 2012 Jan 16. J Mol Diagn. 2012. PMID: 22251610 Free article.
Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, van Noesel MM, Caron HN, van der Schoot CE, Hero B, Tytgat GAM. van Wezel EM, et al. Among authors: zappeij kannegieter l. Eur J Cancer. 2016 Feb;54:149-158. doi: 10.1016/j.ejca.2015.11.007. Epub 2016 Jan 12. Eur J Cancer. 2016. PMID: 26796600
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.
van Wezel EM, Stutterheim J, Vree F, Zappeij-Kannegieter L, Decarolis B, Hero B, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, Voermans C, van Noesel MM, Caron HN, van der Schoot CE, Tytgat GA; GPOH MRD Study Group. van Wezel EM, et al. Among authors: zappeij kannegieter l. Pediatr Blood Cancer. 2015 Aug;62(8):1368-73. doi: 10.1002/pbc.25507. Epub 2015 May 4. Pediatr Blood Cancer. 2015. PMID: 25939774
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel.
van Wezel EM, van Zogchel LMJ, van Wijk J, Timmerman I, Vo NK, Zappeij-Kannegieter L, deCarolis B, Simon T, van Noesel MM, Molenaar JJ, van Groningen T, Versteeg R, Caron HN, van der Schoot CE, Koster J, van Nes J, Tytgat GAM. van Wezel EM, et al. Among authors: zappeij kannegieter l. JCO Precis Oncol. 2019 Oct 3;3:PO.18.00413. doi: 10.1200/PO.18.00413. eCollection 2019. JCO Precis Oncol. 2019. PMID: 34036221 Free PMC article.
12 results